Stay updated on GSK2636771 Combo with Pembrolizumab in Melanoma Clinical Trial
Sign up to get notified when there's something new on the GSK2636771 Combo with Pembrolizumab in Melanoma Clinical Trial page.

Latest updates to the GSK2636771 Combo with Pembrolizumab in Melanoma Clinical Trial page
- Check3 days agoChange DetectedVersion updated from v3.0.1 to v3.0.2. The 'Back to Top' element was removed.SummaryDifference0.6%
- Check11 days agoChange DetectedThe web page has been updated from version 3.0.0 to version 3.0.1, indicating a revision in the content.SummaryDifference0.6%
- Check18 days agoChange DetectedThe web page has undergone significant updates, including the addition of a facility name and location, along with multiple study status updates spanning several years. However, several location-related terms have been removed.SummaryDifference28%
- Check25 days agoNo Change Detected
- Check32 days agoChange DetectedThe web page has been updated from version v2.16.11 to v2.16.12.SummaryDifference0.3%
- Check39 days agoChange DetectedThe web page has been updated from version 2.16.10 to version 2.16.11.SummaryDifference0.3%
- Check46 days agoChange DetectedThe web page has removed a service alert regarding planned maintenance and updated the version information. Additionally, a date has been deleted.SummaryDifference5%
Stay in the know with updates to GSK2636771 Combo with Pembrolizumab in Melanoma Clinical Trial
Enter your email address, and we'll notify you when there's something new on the GSK2636771 Combo with Pembrolizumab in Melanoma Clinical Trial page.